HistoSonics Secures $2.25B Acquisition by Consortium Led by K5 Global, Bezos Expeditions, and Johnson & Johnson to Advance Non-Invasive Histotripsy Platform

HistoSonicsAnnouncementItsMajority SharesAuthorityAcquired by a consortium for$2.25 Billion Acquisition, Consortium byK5 Global、Bezos Expeditions, Wellington Management, Johnson & Johnson (Johnson & Johnson - JJDC）、 Amzak Health, HealthQuest Capital, Yonjin Ventureetc.Composition. After the acquisition,HistoSonicsCurrent CEOMike BlueWill continue to serve as CEO, while also serving asChairman of the Board.

Executive Evaluation

"We are always committed to providing breakthrough treatments to patients in a more efficient and larger-scale manner. The support from new investors for disruptive technologies will accelerate our expansion into new clinical indications and global markets."

---Mike Blue  HistoSonics CEO

Consortium Evaluation

"HistoSonics not only possesses revolutionary technology but also demonstrates exceptional execution in translating scientific research into clinical applications. The surge in global hospital orders and clinical efficacy data underscores its value."

---Bryan Baum  Co-founder of K5 Global

It was reported in May this yearMultiple consortia and enterprises (Medtronic, GE, and Johnson & Johnson, etc.) toHistoSonicsInterested. At the time, rumors suggested an acquisition exceeding $2.5 billion.HistoSonics. NowadaysHistoSonicsByK5 Global-led Consortium Acquires for $2.25 Billion, Close to Previously Rumored Price.

HistoSonicsThe reason it is so valuable is based on itsNon-invasive Ultrasound Ablation Tumor RobotEdisonExcellent clinical outcomes in tumor treatment. Clinical data announced in April.Results Show 95.5% Complete Ablation of Liver Cancer.

Specific Research Data

• Primary efficacy endpoint achievement rate: 95.5% (42/44 tumors completely ablated)

• Primary safety endpoint achieved, with only 6.8% (3/44) of patients experiencing major complications.

• Only 1 case of non-serious device-related adverse event occurred 30 days later, and it resolved on its own.

• 19 cases were HCC patients, and 28 cases were metastatic tumors (39.3% originating from colorectal cancer). The 12-month local tumor control rate reached 90%, surpassing current standard local therapies.

As can be seen from the clinical dataEdisonHuge market potential. It not only enables precise ablation of lesions but also allows doctors to monitor the treatment process through a real-time visualization system, with recovery speed in the treated area significantly better than traditional therapies. Besides liver cancer,EdisonIt will also expand to other tumors, such as renal cancer and pancreatic cancer.

Due to its significant efficacy, since its market launch, it has completed over 2,000 liver cancer treatments in more than 50 top hospitals across the United States. And by the end of this year, it will...New Installation50 setsEdison, indicating that the market is growing very rapidly with enormous potential.

Edison

EdisonIt is a sophisticated energy platform that includes a robotic arm, an ultrasound probe, an imaging display, and a control panel, with an embedded microcomputer responsible for image computation and controlling the movement of the robotic arm. It can deliver pulsed acoustic wave energy into the human body without any incisions or needles and is capable of disrupting tissue at the subcellular level. Physicians can monitor the "bubble cloud" and treatment effects in real time via the device’s display.

EdisonAble to provide patients with precise, controllable, personalized, and tissue-specific treatments.

Tissue fission uses pulsed sound waves to induce "bubble clouds" from naturally occurring gases within the target tissue. These bubble clouds form and collapse within microseconds, generating mechanical forces sufficient to disrupt tissue at cellular and subcellular levels through a non-invasive and non-thermal method.